Proceedings of the 4th International Conference Current Breakthrough in Pharmacy (ICB-Pharma 2022)

<Previous Article In Volume
Next Article In Volume>

Review: Diphenylphosphane Derivatives of Ketoconazole and Oteseconazole/VT-1161, Promising New Azole Compounds in the Treatment of Candida albicans Infections

Authors
Muhammad Rosyid As Sabiq1, 2, Peni Indrayudha1, *
1Faculty of Pharmacy, Universitas Muhammadiyah Surakarta (UMS), Jl. A. Yani Tromol Pos I, Pabelan, Kartasura, Sukoharjo, Indonesia
2Master of Pharmacy, Graduate School of Universitas Muhammadiyah Surakarta, Jl. A. Yani Tromol Pos I, Pabelan, Kartasura, Sukoharjo, Indonesia
*Corresponding author. Email: peni.indrayudha@ums.ac.id
Corresponding Author
Peni Indrayudha
Available Online 14 December 2022.
DOI
10.2991/978-94-6463-050-3_27How to use a DOI?
Keywords
“Diphenylphosphane derivatives of ketoconazole”; oteseconazole; VT-1161; “Candida albicans”
Abstract

In some treatments of diseases, there is a risk of possible fungal infection of Candida albicans. The risk of infection can be exacerbated by the occurrence of resistance to anti-fungal drugs, including resistance to azole compounds. The purpose of this research is to conduct a review of new azole compounds in the treatment of Candida albicans infections. This study uses a literature review method. The source of the data for this research comes from journals that have been published and indexed in the PubMed search with several inclusion and exclusion criteria. The results showed that all new drug candidates of azoles showed excellent antifungal activity against Candida albicans in vitro. In general, all azoles have a similar mechanism of action of inhibiting the enzyme 14α-demethylase (CYP51) through competitive inhibition. Inhibition of CYP51 causes fungal cells to lose ergosterol, implicated in cell death. The new azole compounds showed stronger CYP51 inhibitory activity and can suppress the growth of fluconazole-resistant strains. The new azole compounds showed better CYP51 inhibitory activity against Candida albicans resistance

Copyright
© 2023 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the 4th International Conference Current Breakthrough in Pharmacy (ICB-Pharma 2022)
Series
Atlantis Highlights in Chemistry and Pharmaceutical Sciences
Publication Date
14 December 2022
ISBN
978-94-6463-050-3
ISSN
2590-3195
DOI
10.2991/978-94-6463-050-3_27How to use a DOI?
Copyright
© 2023 The Author(s)
Open Access
Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Cite this article

risenwbib
TY  - CONF
AU  - Muhammad Rosyid As Sabiq
AU  - Peni Indrayudha
PY  - 2022
DA  - 2022/12/14
TI  - Review: Diphenylphosphane Derivatives of Ketoconazole and Oteseconazole/VT-1161, Promising New Azole Compounds in the Treatment of Candida albicans Infections
BT  - Proceedings of the 4th International Conference Current Breakthrough in Pharmacy (ICB-Pharma 2022)
PB  - Atlantis Press
SP  - 318
EP  - 328
SN  - 2590-3195
UR  - https://doi.org/10.2991/978-94-6463-050-3_27
DO  - 10.2991/978-94-6463-050-3_27
ID  - Sabiq2022
ER  -